12.12.2023 • NewsSyensqoSolvaydemerger

Syensqo is Created Following Demerger of Solvay

Solvay’s shareholders supported the separation with 99.53 % approval, giving official birth to Syensqo.

As the Extraordinary General Shareholders’ Meeting of Solvay closed last week with massive support (+99.53%) of shareholders, Syensqo will be officially demerged from Solvay.

“This is a historical moment,” commented Ilham Kadri, incoming CEO of Syensqo. “This turning point highlights the recognition and success of the in-depth transformation of Solvay in the past 5 years. I want to thank all our shareholders, board members, and teams for their trust, and for making this ambitious project come true. I also wish the new Solvay a very bright future."

Solvay's newly established pure-play company, among the world's largest, is set to uphold the innovative legacy of its founder Ernest Solvay. Branded as Syensqo, the company aims to enhance its innovation capabilities, serving customers' environmental goals, achieving carbon neutrality by 2040, and driving growth in disruptive technologies.

Solvay’s extraordinary shareholders’ meeting supported the separation with...
Solvay’s extraordinary shareholders’ meeting supported the separation with 99.53 % of positive votes, giving official birth to Syensqo. © Syensqo

Company

Syensqo

rue de la Fusée 98
B-1130 Brussels
Belgium

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.